Lilly Bracing For Possible Medicare Non-Coverage Or CED Decision On Amyvid
This article was originally published in The Pink Sheet Daily
Executive Summary
Lilly executives discuss likely outcomes of a pending CMS draft decision on Medicare coverage for the beta amyloid imaging agent Amyvid, emphasizing that a decision for non-coverage or coverage with evidence development would be a major setback for research and development in Alzheimer’s disease.